Cite this DOI

Longman Publishers (2020). Formulation, Development and Evaluation of Topiramate Loaded Niosomes for the Treatment of Epilepsy. *Journal of Science & Technology*, 119–129. https://doi.org/10.46243/jst.2020.v5.i5.pp119-129

@article{anon2020formulation,
  title     = {{Formulation, Development and Evaluation of Topiramate Loaded Niosomes for the Treatment of Epilepsy}},
  journal   = {Journal of Science \& Technology},
  year      = {2020},
  month     = {oct},
  number    = {Volume 5},
  pages     = {119--129},
  publisher = {Longman Publishers},
  issn      = {2456-5660},
  doi       = {10.46243/jst.2020.v5.i5.pp119-129},
  url       = {https://doi.org/10.46243/jst.2020.v5.i5.pp119-129},
  language  = {en},
  abstract  = {Topiramate (TPM) is an anti-epileptic drug used in the treatment of epilepsy and seizures. The study was designed with three aims. First, to enhance the solubility and bioavailability of BCS class III drug TPM; second, to ease administration of the formulation to the epileptic patient, during an attack, and third, to decrease the dose of drug for enduring treatment. Formulation of TPM niosomes was optimized by changing the concentration of Tween, Labrafil and cholesterol using response surface design. Further the TPM niosomes were prepared by using ether injection method. The formulation was then evaluated for vesicle size, entrapment efficiency and in-vitro drug release study. FTIR and DSC studies were performed for pure drug and optimized batch. The vesicle size of the optimized batch was found to be 0. 35 nm. The \%entrapment efficiency and \%drug release of optimized batch was found to be 94.64\% and 92.027\% respectively. From the present study it can be concluded that the developed niosomes of TPM has shown great potential in treatment of epilepsy.}
}

TY  - JOUR
TI  - Formulation, Development and Evaluation of Topiramate Loaded Niosomes for the Treatment of Epilepsy
JO  - Journal of Science & Technology
PY  - 2020
DA  - 2020/10/12/
IS  - Volume 5
SP  - 119
EP  - 129
PB  - Longman Publishers
SN  - 2456-5660
LA  - en
AB  - Topiramate (TPM) is an anti-epileptic drug used in the treatment of epilepsy and seizures. The study was designed with three aims. First, to enhance the solubility and bioavailability of BCS class III drug TPM; second, to ease administration of the formulation to the epileptic patient, during an attack, and third, to decrease the dose of drug for enduring treatment. Formulation of TPM niosomes was optimized by changing the concentration of Tween, Labrafil and cholesterol using response surface design. Further the TPM niosomes were prepared by using ether injection method. The formulation was then evaluated for vesicle size, entrapment efficiency and in-vitro drug release study. FTIR and DSC studies were performed for pure drug and optimized batch. The vesicle size of the optimized batch was found to be 0. 35 nm. The %entrapment efficiency and %drug release of optimized batch was found to be 94.64% and 92.027% respectively. From the present study it can be concluded that the developed niosomes of TPM has shown great potential in treatment of epilepsy.
DO  - 10.46243/jst.2020.v5.i5.pp119-129
UR  - https://doi.org/10.46243/jst.2020.v5.i5.pp119-129
ER  -

{
    "type": "article-journal",
    "id": "10.46243/jst.2020.v5.i5.pp119-129",
    "DOI": "10.46243/jst.2020.v5.i5.pp119-129",
    "URL": "https://doi.org/10.46243/jst.2020.v5.i5.pp119-129",
    "title": "Formulation, Development and Evaluation of Topiramate Loaded Niosomes for the Treatment of Epilepsy",
    "source": "Smart Scholars DOI Registry",
    "container-title": "Journal of Science & Technology",
    "issued": {
        "date-parts": [
            [
                2020,
                10,
                12
            ]
        ]
    },
    "issue": "Volume 5",
    "page": "119-129",
    "publisher": "Longman Publishers",
    "language": "en",
    "abstract": "Topiramate (TPM) is an anti-epileptic drug used in the treatment of epilepsy and seizures. The study was designed with three aims. First, to enhance the solubility and bioavailability of BCS class III drug TPM; second, to ease administration of the formulation to the epileptic patient, during an attack, and third, to decrease the dose of drug for enduring treatment. Formulation of TPM niosomes was optimized by changing the concentration of Tween, Labrafil and cholesterol using response surface design. Further the TPM niosomes were prepared by using ether injection method. The formulation was then evaluated for vesicle size, entrapment efficiency and in-vitro drug release study. FTIR and DSC studies were performed for pure drug and optimized batch. The vesicle size of the optimized batch was found to be 0. 35 nm. The %entrapment efficiency and %drug release of optimized batch was found to be 94.64% and 92.027% respectively. From the present study it can be concluded that the developed niosomes of TPM has shown great potential in treatment of epilepsy.",
    "ISSN": "2456-5660"
}

From the record as registered (version 2) — the record and its history. Programs: https://registry.smartscholars.in/api.php?action=cite&doi=10.46243%2Fjst.2020.v5.i5.pp119-129 gives all four in one JSON answer.